SIOUX FALLS, S.D., Nov. 20, 2023 SAB Biotherapeutics , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte.
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte
SAB Biotherapeutics (SABS) Appoints Katie Ellias to the Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.